AusCann Group Holdings Ltd (ASX: AC8) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Auscann Group Holdings Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $50.66 million
P/E Ratio N/A
Dividend Yield N/A
Shares Outstanding 440.55 million
Earnings per share -0.026
Dividend per share N/A
Year To Date Return -41.03%
Earnings Yield N/A
Franking N/A
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

AC8 ASX Announcements

An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
YesNo

About AusCann Group Holdings Ltd

Auscann Group Holdings Ltd (ASX: AC8) is a pharmaceutical company based in Western Australia. Its focus is on developing, producing and distributing a range of cannabinoid treatments for use in Australia and internationally.

According to Auscann, the company’s products are the result of a stringent development program that aims to produce stable and effective cannabinoid-based medicines. Auscann also seeks to generate clinical evidence supporting the efficacy of its products to support further market penetration.

Whilst working directly with patients, Auscann’s primary focus is on providing healthcare professionals with optimal treatment solutions to help them better care for their patients. The company also provides healthcare professionals with the tools to personalise and adjust dosage and treatment programs for each individual.

AusCann was readmitted to the ASX in early 2017 after it was acquired by the already listed company TW Holdings Limited. In the months following, the Auscann share price surged by nearly 200%. Within 12 months, the Auscann share price had gone on to deliver growth of nearly 500% over its ASX readmittance value. Since then however, the Auscann share price has trended lower and has not traded over $1 since late 2018.

AC8 Share Price History Data provided by Morningstar.

Data provided by Morningstar.
Date Close Change % Change Volume Open High Low
11 Jun 2021 $0.12 $0.00 0.00% 596,946 $0.12 $0.12 $0.12
10 Jun 2021 $0.12 $0.00 0.00% 224,830 $0.12 $0.12 $0.12
09 Jun 2021 $0.12 $0.00 0.00% 458,416 $0.12 $0.12 $0.12
08 Jun 2021 $0.12 $0.00 0.00% 489,332 $0.12 $0.12 $0.12
07 Jun 2021 $0.12 $0.00 0.00% 357,789 $0.12 $0.12 $0.12
04 Jun 2021 $0.12 $-0.01 -7.69% 1,058,098 $0.13 $0.13 $0.12
03 Jun 2021 $0.13 $0.01 8.33% 1,637,443 $0.12 $0.13 $0.12
02 Jun 2021 $0.12 $0.00 0.00% 250,822 $0.12 $0.12 $0.12
01 Jun 2021 $0.12 $0.00 0.00% 1,160,946 $0.12 $0.12 $0.12
31 May 2021 $0.12 $0.00 0.00% 510,852 $0.12 $0.12 $0.11
28 May 2021 $0.12 $0.01 9.09% 1,409,038 $0.11 $0.12 $0.11
27 May 2021 $0.11 $0.00 0.00% 675,788 $0.11 $0.11 $0.11
26 May 2021 $0.11 $0.00 0.00% 443,285 $0.12 $0.12 $0.11
25 May 2021 $0.11 $0.00 0.00% 411,268 $0.11 $0.11 $0.11
24 May 2021 $0.11 $0.00 0.00% 779,665 $0.12 $0.12 $0.11
21 May 2021 $0.11 $-0.01 -8.70% 1,048,327 $0.12 $0.12 $0.11
20 May 2021 $0.12 $0.00 0.00% 431,090 $0.12 $0.12 $0.12
19 May 2021 $0.12 $0.01 9.09% 1,211,099 $0.11 $0.12 $0.11
18 May 2021 $0.11 $0.00 0.00% 428,252 $0.12 $0.12 $0.11
17 May 2021 $0.11 $-0.01 -8.33% 661,921 $0.12 $0.12 $0.11

Director Transactions Data provided by Morningstar.

Data provided by Morningstar.
Date Director Type Amount Value Notes
14 May 2021 Geoff Starr Buy 100 $11,500
On-market trade.
15 Apr 2021 Robert (Max) Johnston Buy 110 $15,400
On-market trade.
18 Mar 2021 Krista Bates Buy 292 $42,412
As advised by the company. Shares acquired under the Scheme of
Arrangement with CannPal Animal
Therapeutics Ltd.
18 Mar 2021 Christopher (Chris) Mews Buy 279 $40,554
As advised by the company. Shares acquired under the Scheme of
Arrangement with CannPal Animal
Therapeutics Ltd (ASX:CP1) under which
CP1 shareholders received 1.3 new AC8
shares for every 1 CP1 share held at the
record date.
18 Mar 2021 Robert (Max) Johnston Buy 390 $56,550
As advised by the company. Shares acquired under the Scheme of
Arrangement with CannPal Animal
Therapeutics Ltd.

Directors & Management Data provided by Morningstar.

Data provided by Morningstar.
Name Title Start Date Profile
Ms Krista Bates Non-Executive Director Dec 2019
Ms Bates brings over 18 years of experience in the legal market. She is currently a Partner at Lavan and is Head of Mining & Resources. Krista has led transactions across multiple sectors advising a base of private and listed companies, private equity funds, governments and individuals, nationally and internationally.
Mr Geoff Starr Non-Executive Director Apr 2021
--
Mr Robert Clifford Non-Executive Director Apr 2021
--
Dr Kathryn (Kate) Claire Adams Non-Executive Director Apr 2021
--
Mr Bruce Fielding McHarrie Non-Executive Director Jan 2017
Mr McHarrie is experienced senior executive and independent company director with a background in the life sciences industry in finance, operations, governance, business and investment management, and strategic planning. He previously served as the Chief Financial Officer, Director of Operations and Director of Strategic Projects with the Telethon Kids Institute in Western Australia. Prior to joining the Institute, Bruce was based in London as an Assistant Director at Rothschild Asset Management in the Bioscience Unit. He co-founded Phylogica Limited and has held a number of other non- executive director positions in biotechnology and not-for-profit healthcare organisations.
Mr Christopher (Chris) Lee Mews Non-Executive Director Dec 2019
Mr Mews is an experienced non-executive director with over 20 years in the financial services sector, having held senior positions in finance, corporate secretarial and compliance in listed and unlisted companies. Chris is currently the Chief Financial Officer and Company Secretary of Merchant Group Pty Ltd.
Mr Robert (Max) Maxwell Johnston Non-Executive DirectorNon-Executive Chairman Dec 2019
Mr Johnston is a health care industry director with a range of executive and pharmaceutical experience. He previously held the position of President and Chief Executive Officer of Johnson & Johnson Pacific for 11 years.
Mr Layton Patrick Mills Chief Executive Officer Mar 2021
-
Ms Susan Patricia Hunter Company Secretary Oct 2016
-
Mr Quentin Heath Megson Chief Financial OfficerJoint Company Secretary Feb 2019
-
Layton Patrick Mills Chief Executive Officer
-
Quentin Heath Megson Chief Financial OfficerJoint Company Secretary
-
Susan Patricia Hunter Company Secretary
-

Top Shareholders Data provided by Morningstar.

Data provided by Morningstar.
Name Shares Capital
The Trust Company (Australia) Limited <M0F> A/C 39,000,000 12.30%
Citicorp Nominees Pty Limited 11,714,708 3.38%
Ms Elaine Lucy Darby 6,816,838 2.15%
Merrill Lynch (Austraua) Nominees Pty Umited 5,875,409 1.85%
Mal Washer Nominees Ft( Ltd 5,300,632 1.67%
J P Morgan Nominees Austraua Limited 4,463,186 1.41%
Mr Warren Sidney Langman 4,235,928 1.34%
HSBC Custody Nominees (Australia) Limited 2,999,292 0.95%
BNP Paribas Nominees Pty Ltd < Ib Au Noms Retail Went Drp> 2,805,532 0.88%
Celtic Capital Pty Ltd <Celtic Capital A/C> 2,348,106 0.73%
Wil & Jack Ft( Ltd <Wil & Jack Family A/C> 2,348,106 0.74%
Mr George Chien Hsun Lu & Mrs Jenny Chin Pao Lu 2,195,000 0.69%
Danny Stephens Investments Pty Ltd <Danny Stephens Family A/C> 2,150,200 0.68%
Mr Anthony Nicholas Nagy 2,061,846 0.65%
Bnp Paribas Noms Pty Ltd < Drp> 1,941,237 0.61%
Pershing Australia Nominees Pty Ltd <Accum A/C> 1,726,435 0.54%
Noldex Pty Ltd 1,573,918 0.50%
Mr George Chien Hsun Lu 1,390,000 0.44%
HSBC Custody Nominees (Australia) Limited (I) 1,257,407 0.40%
Alava Holdings Limited 1,250,000 0.39%

Profile

since

Note